Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone

REFERENCES

• Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Thalassemia clinical research network. Complications of β-thalassemia major in North America. Blood. 2004;104:34–39.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. The β-thalassemias. N Engl J Med. 1999;341:99–109.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227–231.
   PubMed Web of Science ®Google Scholar
• Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26–36.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574–578.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739–761.
   PubMed Web of Science ®Google Scholar
• Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci. 1964;119:758–768.
   PubMed Web of Science ®Google Scholar
• Lee P, Mohammed N, Marshall RD, et al. Intravenous infusion pharmacokinetics of desferrioxamine and its relation to iron metabolism. Drug Metab Dispos. l993;21:640–644.
   Google Scholar
• Marcus RE, Davies SG, Bantock HM, Underwood SR, Walton S, Huehns ER. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet. 1984;l:392–393.
   Google Scholar
• Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenotis desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127:348–355.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr. 1997;130:86–88.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Grady RW, Dragsten P, et al. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator. Br J Haematol. 2007;138:374–381.
   PubMedGoogle Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89: 1187–1193.
   PubMed Web of Science ®Google Scholar
• Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229–1236.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drtigs. Toxicol Lett. 1995;80:l–18.
   Google Scholar
• Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IYR. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet. 1992;l:699–701.
   Google Scholar
• Sofroniadou K, Drossou M, Foundoulaki M, Konstantopoulos K, Kyriakou D, Zervas J. Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine). Drug Saf. 1990;5:152–154.
   PubMed Web of Science ®Google Scholar
• Sharnetzky M, Konig R, Lamomek M, Tillmann W, Schroter W. Prophylaxis of systemic yersiniasis in thalassemia major. Lancet. 1984;2:79.
   Google Scholar
• Modell B, Khan M, Darlison M. Survival in P-thalassaemia major in the UK: data from the UK register. Lancet. 2000;355:2051–2052.
   PubMed Web of Science ®Google Scholar
• Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263–269.
   PubMed Web of Science ®Google Scholar
• Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr. 1981;137:267–271.
   PubMed Web of Science ®Google Scholar
• Pippard MJ, Weatherall DJ. Iron balance and the management of iron overload in β-thalassemia intermedia. Birth Defects Orig Artic Ser. 1988;23:29–33.
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Pattichis K, Neocleotis K, Kolnagou A. The design and development of deferiprone (Ll) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem. 2004;11:2161–2183.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Ll (l,2-dimethyl-3-hydroxypyrid-4-one). Drugs Future. 1988;13:413–415.
   Google Scholar
• Kontoghiorghes GJ, GoddardJ G, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator l,2-dimethyl-3-hydroxypyrid-4one. Clin Pharm Ther. 1990;48:255–261.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. New concepts of iron and altiminitim chelation therapy with oral Ll (Deferiprone) and other chelators. Analyst. 1995;120:845–851.
   PubMed Web of Science ®Google Scholar
• Sheppard L, Kontoghiorghes GJ. Synthesis and metabolism of Ll and other novel a-ketohydroxypyridine iron chelators and their metal complexes. Drugs Today. 1992;28:3–10.
   Google Scholar
• Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, et al. Long term trial with the oral chelator l,2-dimethyl-3-hydroxypyrid-4-one (Ll). (I) Iron chelation and metabolic studies. Br J Haematol. 1990;76:295–300.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Bartlett AN, Sheppard L, Barr J, Nortey P. Oral iron chelation therapy with deferiprone (Ll): Monitoring of biochemical, drtig and iron excretion changes. Arzn Forsch/Drug Res. 1995;45:65–69.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Loren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. 1990;336:1275–1279.
   PubMed Web of Science ®Google Scholar
• Collins AF, Fassos FF, Stobie S, et al. Iron balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1) in iron-loaded patients with sickle cell disease. Blood. 1994;83:2329–2333.
   PubMed Web of Science ®Google Scholar
• Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassaemia: Indian trial. Br J Haematol. 1992;82: 460–466.
   PubMed Web of Science ®Google Scholar
• Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187–189.
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24.
   PubMed Web of Science ®Google Scholar
• Cohen AR. New advances in iron chelation therapy. Hematology Am Soc Hematol Educ Program. 2006;42–47.
   PubMedGoogle Scholar
• Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332:918–922.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417–423.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583–1587.
   PubMed Web of Science ®Google Scholar
• Maggio A, D'Amico GD, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cell Mol Dis. 2002;28:196–208.
   PubMed Web of Science ®Google Scholar
• Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361–364.
   PubMed Web of Science ®Google Scholar
• Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cell Mol Dis. 2006;36:21–25.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79:2741–2748.
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122:305–310.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in β thalassaemia. Lancet. 2002;360:516–520.
   PubMed Web of Science ®Google Scholar
• Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489–496.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, DeStefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferipronetreated patients with thalassemia major. Blood. 2006;107:3733–3737.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738–3744.
   PubMed Web of Science ®Google Scholar
• Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–287.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–1884.
   PubMed Web of Science ®Google Scholar
• Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson. 2009;11:20.
   PubMed Web of Science ®Google Scholar
• Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens. Eur J Haematol. 2007;78:52–57.
   PubMed Web of Science ®Google Scholar
• Perifanis V, Christoforidis A, Vlachaki E, Tsatra I, Spanos G, Athanassiou-Metaxa M. A comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major. Int J Hematol. 2007;86:385–389.
   PubMed Web of Science ®Google Scholar
• Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145:245–254.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia. 2nd rev. ed. Nicosia, Cyprus: Thalassaemia International Federation; 2008.
   Google Scholar
• Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37:12–20.
   PubMed Web of Science ®Google Scholar